NasdaqGS - Nasdaq Real Time Price USD

Repare Therapeutics Inc. (RPTX)

Compare
3.5400 +0.0100 (+0.28%)
At close: June 24 at 4:00 PM EDT
3.5500 +0.01 (+0.28%)
After hours: June 24 at 4:03 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
97,859.0000
51,133.0000
131,830.0000
7,600.0000
135.0000
--
Operating Expense
168,586.0000
167,357.0000
151,626.0000
116,260.0000
54,437.0000
--
Operating Income
-70,727.0000
-116,224.0000
-19,796.0000
-108,660.0000
-54,302.0000
--
Net Non Operating Interest Income Expense
12,875.0000
13,334.0000
5,631.0000
259.0000
240.0000
--
Other Income Expense
-211.0000
-289.0000
265.0000
-185.0000
-680.0000
--
Pretax Income
-58,063.0000
-103,179.0000
-13,900.0000
-108,586.0000
-54,742.0000
--
Tax Provision
-12,370.0000
-9,383.0000
15,147.0000
-1,678.0000
-1,325.0000
--
Net Income Common Stockholders
-45,693.0000
-93,796.0000
-29,047.0000
-106,908.0000
-53,417.0000
--
Diluted NI Available to Com Stockholders
-45,693.0000
-93,796.0000
-29,047.0000
-106,908.0000
-53,417.0000
--
Basic EPS
-1.09
--
-0.69
-2.83
-2.66
-1.17
Diluted EPS
-1.10
--
-0.69
-2.83
-2.66
-1.17
Basic Average Shares
42,141.6250
--
41,922.0420
37,818.1150
20,045.6020
23,192.4490
Diluted Average Shares
42,589.1740
--
41,922.0420
37,818.1150
20,045.6020
23,192.4490
Total Operating Income as Reported
-70,727.0000
-116,224.0000
-19,796.0000
-108,660.0000
-54,302.0000
--
Total Expenses
168,586.0000
167,357.0000
151,626.0000
116,260.0000
54,437.0000
--
Net Income from Continuing & Discontinued Operation
-45,693.0000
-93,796.0000
-29,047.0000
-106,908.0000
-53,417.0000
--
Normalized Income
-45,627.6827
-93,641.4596
-29,274.2732
-106,766.2253
-52,769.0718
--
Interest Income
12,875.0000
13,334.0000
5,631.0000
259.0000
240.0000
--
Net Interest Income
12,875.0000
13,334.0000
5,631.0000
259.0000
240.0000
--
EBIT
-70,727.0000
-116,224.0000
-19,796.0000
-108,660.0000
-54,302.0000
--
EBITDA
-68,716.0000
-114,273.0000
-17,818.0000
-107,189.0000
-53,405.0000
--
Reconciled Depreciation
2,011.0000
1,951.0000
1,978.0000
1,471.0000
897.0000
--
Net Income from Continuing Operation Net Minority Interest
-45,693.0000
-93,796.0000
-29,047.0000
-106,908.0000
-53,417.0000
--
Total Unusual Items Excluding Goodwill
-83.0000
-170.0000
308.0000
-144.0000
-664.0000
--
Total Unusual Items
-83.0000
-170.0000
308.0000
-144.0000
-664.0000
--
Normalized EBITDA
-68,633.0000
-114,103.0000
-18,126.0000
-107,045.0000
-52,741.0000
--
Tax Rate for Calcs
0.0002
0.0001
0.0003
0.0000
0.0000
--
Tax Effect of Unusual Items
-17.6827
-15.4596
80.7268
-2.2253
-16.0718
--
12/31/2019 - 6/19/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PMVP PMV Pharmaceuticals, Inc.
1.6900
+4.64%
 
PASG Passage Bio, Inc.
0.9100
0.00%
 
RLAY Relay Therapeutics, Inc.
6.90
-0.58%
 
SEER Seer, Inc.
1.7300
+1.76%
 
ALXO ALX Oncology Holdings Inc.
6.55
-0.15%
 
TNGX Tango Therapeutics, Inc.
10.15
+0.50%
 
ADVM Adverum Biotechnologies, Inc.
6.84
+1.63%
 
APLT Applied Therapeutics, Inc.
4.6300
+1.76%
 
QURE uniQure N.V.
4.5400
-1.09%
 
SRRK Scholar Rock Holding Corporation
8.41
-0.47%